{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-039228","form_type":"8-K","ticker":"BCTX","cik":"0001610820","company_name":"BriaCell Therapeutics Corp.","filed_at":"2023-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.773047+00:00","generated_at":"2026-06-08T22:26:46.940346+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BriaCell receives FDA clearance for Bria-OTS IND; reports preclinical data at SITC","bullets":["FDA authorized Bria-OTS IND for clinical study of off-the-shelf personalized breast cancer immunotherapy.","Preclinical data at SITC 2023 shows broad immune activation in tumor models by next-gen Bria-OTS+ and Bria-PROS+.","Data indicates personalized HLA-matched platform covers >99% of US population with favorable safety profile.","BriaCell expects to initiate clinical study of Bria-OTS and advance advanced versions for breast and prostate cancers."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-039228","json":"https://secwatch.observer/filing/0001493152-23-039228.json","markdown":"https://secwatch.observer/filing/0001493152-23-039228.md","text":"https://secwatch.observer/filing/0001493152-23-039228.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223039228/0001493152-23-039228-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223039228/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T22:26:46.940346+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}